Blood Cancer Journal Contents: 31 Oct 2022

The latest content from Blood Cancer Journal: 31 October 2022

High efficacy of Azacitidine plus HAG in acute myeloid leukemia: an open-label, single-arm, multi-center, phase 2 study Jun Li, Qi Han [...] Zheng Ge Correspondence | 28 October 2022 | Article number: 145 |  doi: 10.1038/s41408-022-00740-3

Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia Aram Bidikian, Hagop Kantarjian [...] Ghayas C. Issa Article | 28 October 2022 | Article number: 144 |  doi: 10.1038/s41408-022-00742-1

Fatal Powassan virus encephalitis in patients with chronic lymphocytic leukemia Isla M. Johnson, Caleb Scheckel [...] Timothy G. Call Correspondence | 07 October 2022 | Article number: 143 |  doi: 10.1038/s41408-022-00737-y

Does the pursuit of scientific excellence serve or hamper translational medical research: an historical perspective from hematological malignancies Chris M. Bunce, Farhat L. Khanim & Mark T. Drayson Review Article | 07 October 2022 | Article number: 142 |  doi: 10.1038/s41408-022-00738-x

TET2 deficiency promotes MDS-associated leukemogenesis Feiteng Huang, Jie Sun [...] Ling Li Correspondence | 04 October 2022 | Article number: 141 |  doi: 10.1038/s41408-022-00739-w

Journal Info Submit Manuscript RSS Feed

This email has been sent to ignoble.experiment@arconati.us by Blood Cancer Journal.

Unsubscribe Manage Alerts Privacy policy Contact us

Springer Nature Limited is a company registered in England and Wales under Company Number 785998 with its registered office at The Campus, 4 Crinan Street, London, N1 9XW, United Kingdom

Nature is part of Springer Nature. © 2022 Springer Nature Limited. All rights reserved.